Description
The KRIBIOLISA Antibodies to S. enterica serovar Typhi (Typhoid) polysaccharide (Vi) IgG ELISA has been designed for the qualitative detection of S. Typhi Vi-specific IgG antibodies in human serum and plasma. The kit is specifically designed to assess the immunogenicity in humans vaccinated with new generation S. Typhi Vi based vaccines (Typhim and Typherix).
The Vi capsular polysaccharide vaccine (or ViCPS) is one of two vaccines recommended by the World Health Organization for the prevention of typhoid (the other is Ty21a). The vaccine was first licensed in the US in 1994 and is made from the purified Vi capsular polysaccharide from the Ty2 Salmonella Typhi strain; it is a subunit vaccine. A newer conjugate form of the vaccine (Vi bound to a non-toxic recombinant Pseudomonas aeruginosa exotoxin, or Vi-rEPA) has enhanced efficacy, including protection of children under 5 years of age. It has been observed that many patients develop immunogenicity to the vaccine, hence it is essential to monitor the patient for any adverse effects.
If you have published a paper by using any of our ELISA since 01/01/2023, kindly fill out the “Krishgen Publication Reward Application Form” with complete information and send it by at email: info@krishgen.com, with the subject “Krishgen Publication Reward”. We will get back to you with the Amazon / Krishgen Credit Reward after we confirm it ASAP!